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Abstract
Introduction
Depression has been shown to be associated with elevated leptin levels, low-grade inflam-
mation and insulin resistance. These derangements are often measured in mixed gender
cohorts despite the different body compositions and hormonal environments of men and
women and gender-specific prevalence and responses to depression.
Methods
A cross-sectional analysis was carried out on a cohort of 639 participants from the ADDI-
TION-Leicester dataset to assess differences in markers of diabetes risk, cardiovascular
risk and inflammation in depressed and non-depressed individuals. Depressive symptoms
were determined using the WHO (Five) well-being index. Multivariate linear and logistic
regression analyses were adjusted for age, sex, ethnicity, body mass index, smoking, social
deprivation and activity levels for continuous and binary variables respectively. Further anal-
ysis included stratifying the data by gender as well as assessing the interaction between
depression and gender by including an interaction term in the model.
Results
Women with depressive symptoms had a 5.3% larger waist circumference (p = 0.003),
28.7% higher HOMA IR levels (p = 0.026), 6.6% higher log-leptin levels (p = 0.01) and
22.37% higher TNF-α levels (p = 0.015) compared with women without. Conversely, depres-
sive symptoms in men were associated with 7.8% lower body fat % (p = 0.015) but 48.7%
higher CRP levels (p = 0.031) compared to men without. However, interaction analysis failed
to show a significant difference between men and women.
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Conclusions
Depressive symptoms are associated with metabolic derangements. Whilst women tended
to show elevations in biomarkers related to an increased risk of type 2 diabetes (HOMA IR,
leptin and TNF-α), men showed a marked increase in the cardiovascular disease risk bio-
marker CRP. However, perhaps due to the cohort size, interaction analysis did not show a
significant gender difference.
1. Introduction
Depression is associated with a significantly increased risk of developing type 2 diabetes
(T2DM) and cardiovascular disease (CVD)[1–3]. A meta-analysis by Mezuk and colleagues
(2008) estimated a 60% increased risk of diabetes [4], whilst Gan et al (2014) estimated a 30%
increased pooled risk for coronary heart disease (CHD) [5]. Depression is also independently
associated with increased risk of mortality [6, 7]. The adverse effects of depression on diabetes
and cardiovascular outcomes have been attributed to poor lifestyle behaviours including:
increased caloric intake and reduced rates of exercise [8, 9]. However, even when these factors
have been controlled for, the association between depression and increased risk of CVD and
T2DM has persisted [1, 5].
The causal pathways linking depression with metabolic dysregulation have not been fully
elucidated, however elevations in insulin resistance (IR), low grade inflammation and leptin
have been repeatedly reported [1, 10–13]. More severe cases of depression have been associated
with activation of the hypothalamic–pituitary–adrenocortical (HPA) axis and sympathetic
nervous system which is known to lead to an increased release of catecholamines which in
turn inhibit insulin-induced uptake of glucose in adipocytes [14–17]. However, this affect is
relatively modest, for instance, a meta-analysis by Kan et al 2013, detected a small increased
risk of IR (d = 0.19 (95% CI: 0.11–0.27)[1]. Cross-sectional studies also show a positive associa-
tion between depression and levels of proinflammatory cytokines but the causal direction can-
not be inferred. Whilst the induction of psychological stress has been shown increase TNF and
IL-6, the reverse has also been observed and high baseline levels and the administration of
proinflammatory cytokines have been shown to precede new onset of depressive symptoms in
prospective studies and clinical trials respectively [18–22]. A further marked feature of depres-
sion is that it appears to be associated with altered leptin homeostasis [13, 23]. High circulating
leptin, a marker of leptin resistance, is independently associated with both IR and CVD [24,
25]. However, the relevance of leptin in depression vs. T2DM and CVD remains unclear due
to the fact that divergent reports have associated depression with both hypo and hyperleptine-
mia [12, 13, 23, 26]. This is further confounded by reports that hyperleptinemia is associated
with both enhanced mood and the onset of depression [27, 28]. Therefore, the potential role of
leptin and the increased prevalence of T2DM and CVD with depression requires further
study.
Most studies analysing depression and metabolic dysfunction have not considered effect
modification by gender. This is despite the marked differences in body mass, body composi-
tion and hormonal milieu of each gender which in turn affects basal levels of CVD markers
(e.g. CRP [29] and clinical measures of T2DM (e.g. HOMA IR [30]). Additionally, the preva-
lence of depression differs with sex, with Kessler and colleagues (1997) reporting a 21.3% prev-
alence in women compared with 12.7% in men [31]; although the risk of mortality from major
chronic diseases is higher in depressed men than in women [32]. Furthermore, studies have
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shown different gender specific responses to depression, for example, increased alcohol use is
twice as likely in men than in women [33]. Therefore the following study had two aims: firstly
to add to the existing evidence that depressive symptoms are linked to markers of T2DM,
CVD and inflammation in a healthy population. Furthermore, we hypothesize that these meta-
bolic disturbances will differ with gender.
2. Methods
This study is a secondary analysis of baseline data collected during the screening phase of the
ADDITION-Leicester study (NCT00318032), an Anglo-Danish-Dutch randomised control
trial assessing of the cost effectiveness of population screening and intensive multi-factorial
intervention for Type 2 diabetes. Details of this cohort have been published elsewhere [34].
The Addition study was carried out in accordance with the latest version of the Declaration of
Helsinki. The study design was approved by the Nottingham Research Ethics Committee, UK
and informed consent of the participants was obtained after the nature of the procedures had
been fully explained. Baseline data and samples were collected from n = 6749 participants
(healthy subjects with no diagnosis of T2DM) between 2004 and 2008. Between 2008 and
2009, n = 987 random samples were assayed for the following biomarkers: leptin, CRP, TNF-
α, IL-6, adiponectin, insulin, PGF, resistin and apolipoprotein A1 & B. On the day of blood
collection, participants were assessed for wellbeing using the WHO (Five) wellbeing index,
scored as a continuous variable with higher values indicating that the participant had experi-
enced a higher level of wellbeing in the 2 weeks preceding the assessment. The possible raw
scores were 0 to 25 and a cut-point of13 was utilised to identify depressive symptoms. Whilst
the WHO (Five) questionnaire does not represent a clinically applicable screen for depression,
it has been shown to be affective in screening for those with a ‘caseness’ for depression. Addi-
tionally, using the cut-off specified, WHO (Five) has been shown to have 100% sensitivity and
78% specificity as a screening tool for depression [35]. WHO (Five) also shows acceptable find-
ings for internal consistency with a Cronbach’s coefficient alpha score of 0.84 [36]. Therefore
for the purposes of this report participants with a WHO (5) score of 13 will be categorised as
displaying depressive symptoms.
Of the 987 participants with biomarker data, 307 were excluded because they had missing
WHO (Five) data. Additionally, a further 41 participants were excluded for: missing ethnicity
data (n = 1), social deprivation scores (n = 7), physical activity scores (n = 31) and/or smoking
status data (n = 3). Therefore 639 participants were included in the current analysis. An analy-
sis of the n = 346 participants that were not included (principally because they had not com-
pleted the WHO (five) questionnaire, n = 307) showed that they were: older, less likely to be
White European, less physically active, more likely to have screen detected T2DM and IGR
and showed a higher index of multiple deprivation; as such, non-inclusion of these participants
may have introduced some sampling bias (S1 Table).
2.1 Population
White Europeans between the ages of 40–75 years and Black and Minority Ethnic (BME) par-
ticipants (predominantly South Asian) between the ages of 25–75 years were included in the
study. A lower age cut-off for BME participants was chosen due to the reported higher risk of
T2DM and CVD. People with the following pre-existing conditions are excluded (general
practice diagnosis and database recorded), T2DM, terminal illnesses with a likely prognosis of
less than 12 months, psychiatric illness likely to hinder informed consent, pregnancy and
lactation.
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2.2 Anthropometric and clinical assessments
Baseline demographic data captured at screening included: age, sex, ethnicity, BMI, smoking,
index of social deprivation and activity levels. Ethnicity status was self-assigned using UK pop-
ulation census categories. Weight (to the nearest 0.1kg) and body fat % (to the nearest 0.1kg)
was measured using Tanita 611 scales (Tanita, West Drayton, UK). Height was measured to
the nearest 0.1cm using a stadiometer. Waist circumference was measured by trained staff
using a non-stretching measuring tape over the tops of the iliac crests. Smoking was self-
reported. Postcode was used to calculate the Index of Multiple Deprivation (IMD), which is a
deprivation score for small areas in England based on a combination of domains encompass-
ing economic, social and housing factors, and enabled ranking of areas according to their
specific level of deprivation [37]. Physical activity was assessed with the short-format Interna-
tional Physical Activity Questionnaire (IPAQ), which assesses moderate to vigorous intensity
activities carried out for greater than 10 minutes within the previous 7 days [38]and was
expressed as metabolic equivalents (METs). Blood biochemistry (HbA1c, glucose and lipids)
was measured by the University Hospitals of Leicester, Clinical Pathology Services. Glucose
tolerance was assessed using a 75g oral glucose tolerance test (OGTT) and participants were
categorised as having normal glucose tolerance (NGT) and impaired glucose regulation (IGR)
according to World Health Organisation criteria (WHO) [39].
2.3 Biomarker measurement
Prior to screening, participants were instructed to fast for 12 hours before the study visit.
Venous blood was collected in EDTA tubes, centrifuged at 1500 g for 10 minutes to produce
plasma, this was then frozen at −80˚C for subsequent measurement of research biomarkers.
Quantitative analysis of plasma for human CRP, ApoA1 and ApoB was carried out on the
ABX Pentra clinical chemistry analyser and latex-enhanced immunoturbidimetric assay (Hor-
iba medical, Northampton, UK). TNF-α and IL-6 were analysed using the Quantikine high
sensitivity ELISA for human TNF-alpha /TNFSF1A and human IL-6 kit, (R&D Systems, UK).
Leptin and resistin was assayed using the Mediagnost human enzyme-immunoassay ELISA
kits (Reutlingen, Germany). Human adiponectin, insulin and 8-Iso prostaglandin F2 (8-Iso-
PG F2) were assayed fluormetrically using the AutoDELFIA 1235 automatic immunoassay sys-
tems (Perkin Elma, Buckinghamshire UK). All samples were analysed in duplicate and with all
duplicate samples having a CV% of20%. All research biomarker assessments were carried
out by University of Leicester Scientists in conjunction with Unilever personnel at the Unilever
Corporate Research Laboratory, Bedford UK.
2.4 Statistical analysis
Demographic variables were presented as mean (SD) or n (%) for continuous and categorical
variables respectively. Differences between the groups with and without depressive symptoms
were estimated using chi-squared tests for categorical variables and t-tests for continuous vari-
ables. Linear regression models were fitted for continuous response variables and logistic
regression models were fitted for binary response variables. All models included a binary
depression case status variable, as well as additional known confounding variables. These
covariates were selected a priori on the basis of previously reported associations with depres-
sion, diabetes or cardiovascular disease. The covariates included were: age, sex, ethnicity, BMI,
IMD, smoking status and physical activity. Adjusted means were calculated from linear regres-
sion models for groups with and without depressive symptoms, whilst odds ratios were calcu-
lated from logistic regression models for the group without depressive symptoms. Models
were fitted for the whole cohort and subsequently stratified by gender. Additionally, the
Depression, metabolic biomarkers and gender
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interaction between depression and gender was assessed by including an interaction term in
the model. Additionally, the analysis was repeated substituting BMI with waist circumference.
Data was analysed using Stata V12.1. No adjustments were made for multiple testing. P values
of0.05 were considered statistically significant.
3. Results
3.1 Study population
The descriptive statistics of the whole cohort are summarised in Table 1. Within the current
study, 25% of the cohort (31.4% of women and 19.4% of men) were categorised as having
depressive symptoms. The cohort with depressive symptoms were less physically active, 2807.5
(3194.7) vs. 3524 (+/-3685.7) METS/week, p = 0.029 and were more likely to be current smok-
ers (p = 0.047) and this is in line with previous findings [8, 40]. There was no significant differ-
ence in the prevalence of NGT, IGR or screen-detected T2DM within each cohort. A data
table outlining the characteristics of the excluded subjects is outlined in S1 Table.
3.2 Study populations stratified by gender
Table 2 outlines the descriptive characteristics of the cohort stratified by gender. Men with
depressive symptoms were younger (p = 0.001) and had 7.8% lower body fat (p = 0.015) than
Table 1. Descriptive characteristics of the study population.
Variable Depressive Symptoms No depressive symptoms All P-valuea
Sex
Male 67 (42.1) 279 (58.1) 346 (54.2) <0.001
Female 92 (57.9) 201 (41.9) 293 (45.9)
Age, years 56.5 (10.6) 59.5 (9.8) 58.7 (10.1) 0.001
Ethnicity
White European 121 (76.1) 373 (77.7) 494 (77.3)
South Asian 36 (22.6) 104 (21.7) 140 (21.9) 0.704
Other 2 (1.3) 3 (0.6) 5 (0.8)
Glycaemia status
Normal glucose tolerance 78 (49.1) 252 (52.5) 330 (51.6) 0.286
Impaired glucose regulation 65 (40.9) 164 (34.2) 229 (35.8)
Type 2 diabetes 15 (9.4) 63 (13.1) 78 (12.2)
Missing 1 (0.6) 1 (0.2) 2 (0.3)
BMI, kg/m2 30.1 (5.2) 29.5 (4.5) 29.6 (4.7) 0.185
Waist circumference, cm 99.1 (13.6) 98.5 (12.3) 98.7 (12.6) 0.636
Smoking status
Non-smoker 87 (54.7) 258 (53.8) 345 (54.0) 0.047
Current smoker 28 (17.6) 53 (11.0) 81 (12.7)
Ex-smoker 44 (27.7) 169 (35.2) 213 (33.3)
IMD Score 20.2 (12.4) 18.7 (12.3) 19.1 (12.3) 0.208
Total METs/week 2807.5 (3194.7) 3524.0 (3685.7) 3345.7 (3580.8) 0.029
Total 159 (100.0) 480 (100.0) 639 (100.0)
All values are n (%) or mean (sd). Abbreviations: BMI, Body Mass Index; IMD, Index of Multiple Deprivation; SD, Standard Deviation. Percentages are in
parenthesis.
a P-values test for a difference between the groups with and without depressive symptoms, and were estimated using chi-squared tests for categorical
variables and t-tests for continuous variables. Missing values for continuous variables: 1 Waist circumference.
https://doi.org/10.1371/journal.pone.0187448.t001
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men without. Women with depressive symptoms were marginally younger (p = 0.061), were
2.5 times more likely to be current smokers (p = 0.029) and had a 5.3% larger waist circumfer-
ence (p = 0.003) than women without.
3.3 Insulin resistance
HOMA IR was not significantly higher in the group with depressive symptoms when analysing
the entire mixed gender cohort (Table 3). However, stratification for gender showed that
HOMA IR (and fasting insulin) was 28.7% higher in women with depressive symptoms vs.
women without (p = 0.026, Table 4). To assess potential mediators of this difference, the covar-
iate BMI was substituted with waist circumference as this was shown to be significantly higher
in women with depressive symptoms within this cohort, whilst BMI and body fat % were
highly comparable in women with and without depressive symptoms (Table 2). Inclusion of
waist circumference as a covariate attenuated the significant association between depressive
symptoms and HOMA IR (p = 0.095, S2 Table), suggesting that the higher HOMA IR levels
were, in part, mediated through higher levels of central obesity, however unadjusted regression
Table 2. Descriptive characteristics of the study population stratified by gender.
Men Women
Variable Depressive
symptoms
(n = 67)
No Depressive symptoms
(n = 279)
P-
valuea
Depressive symptoms
(n = 92)
No Depressive s symptoms
(n(n = 201)
P-
valuea
Age, years 54.4 (10.2) 58.8 (9.9) 0.001 58.0 (10.7) 60.4 (9.7) 0.061
Ethnicity
White European 51 (76.1) 208 (74.6) 0.791 70 (76.1) 165 (82.1)
South Asian 16 (23.9) 71 (25.5) 20 (21.7) 33 (16.4) 0.486
Other 0 (0.0) 0 (0.0) 2 (2.2) 3 (1.5)
Glycaemia status
Normal glucose
tolerance
34 (50.8) 142 (50.9) 0.923 44 (47.8) 110 (54.7) 0.172
Impaired glucose
regulation
24 (35.8) 93 (33.3) 41 (44.6) 71 (35.3)
Type 2 diabetes 9 (13.4) 43 (15.4) 6 (6.5) 20 (10.0)
Missing 0 (0.0) 1 (0.4) 1 (1.1) 0 (0.0)
BMI, kg/m2 28.7 (4.4) 29.3 (3.9) 0.284 31.0 (5.6) 29.7 (5.3) 0.057
Waist circumference,
cm
101.3 (11.5) 102.8 (10.9) 0.312 97.5 (14.8) 92.6 (11.8) 0.003
Body fat % 28.1 (7.0) 30.3 (6.4) 0.015 41.3 (7.2) 40.1 (5.9) 0.129
Smoking status
Non-smoker 31 (46.3) 122 (43.7) 0.415 56 (60.9) 136 (67.7) 0.029
Current smoker 13 (19.4) 40 (14.3) 15 (16.3) 13 (6.5)
Ex-smoker 23 (34.3) 117 (41.9) 21 (22.8) 52 (25.9)
IMD Score 19.1 (11.9) 18.4 (11.5) 0.639 20.9 (12.8) 19.2 (13.3) 0.304
Total METs/week 3528.6 (3871.4) 4091 (4221.1) 0.320 2282.3 (2487.7) 2736.7 (2587.7) 0.159
Total 67 (100.0) 279 (100.0) 92 (100.0) 201 (100.0)
All values are n (%) or mean (sd). Abbreviations: BMI, Body Mass Index; IMD, Index of Multiple Deprivation; SD, Standard Deviation. Percentages are in
parenthesis.
a P-values test for a difference between participants with and without depressive symptoms, and were estimated using chi-squared tests for categorical
variables and t-tests for continuous variables.
Missing values for continuous variables: 1 Waist circumference; 8 Body fat %.
https://doi.org/10.1371/journal.pone.0187448.t002
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analysis between HOMA IR and waist circumference showed only a moderate association R2
= 0.188. Despite the depression-linked elevation in IR in women, HOMA IR levels were higher
in men compared with women (p = 0.005)
3.4 Leptin
Levels of leptin were examined as continuous, log-transformed values and were higher with
depressive symptoms (p =<0.013, Table 3). Stratification based on gender revealed that log-
leptin was 6.6% higher in women with depressive symptoms compared with women without
(p = 0.01, Table 4). Mediation analysis revealed that this association was in part mediated
through central obesity as substituting BMI with waist circumference attenuated the associa-
tion (p = 0.112, S2 Table). Indeed, unadjusted regression analysis between log-leptin and waist
circumference showed only a moderate association R2 = 0.368. Leptin was significantly higher
in women vs. men (p =<0.001).
3.5 Inflammation
3.5.1TNF-α. When analysing the entire mixed gender cohort, TNF-α was not signifi-
cantly higher in the group with depressive symptoms (Table 3), however stratification for gen-
der showed that TNF-α was 22.3% higher in women with depressive symptoms vs. women
without (p = 0.015, Table 4). Substitution of BMI with waist circumference did not attenuate
this association (p = 0.016, S2 Table) and this is reflected by the finding that regression analysis
of waist circumference and TNF-α showed a negligible association, R2 = 0.002. Further analy-
sis showed that TNF-α levels in men and women were comparable (p = 0.486).
3.5.2 CRP. CRP was also higher with depressive symptoms when assessing the entire
cohort (p = 0.041, Table 3). Stratification for gender showed that CRP was 49% higher in
men with depressive symptoms vs. men without (p = 0.031, Table 4) whilst no significant
Table 3. A comparison of participants with and without depressive symptoms, adjusted data.
Adjusted mean (95% CI)a
Variable Depressive symptoms
(n = 159)
No depressive symptoms
(n = 480)
P-value
Resistin ng/ml 5.85 (5.01, 6.69) 5.68 (5.19, 6.16) 0.858
Apo B ng/ml 1.11 (1.06, 1.16) 1.15 (1.12, 1.18) 0.273
Apo A ng/ml 1.58 (1.52, 1.63) 1.54 (1.51, 1.57) 0.388
HDL cholesterol mmol/L 1.36 (1.31, 1.41) 1.33 (1.30, 1.36) 0.600
LDL cholesterol mmol/L 3.46 (3.30, 3.61) 3.61 (3.52, 3.70) 0.119
IL-6pg/ml 2.70 (2.38, 3.02) 2.51 (2.33, 2.70) 0.328
TNF-alpha ng/ml 1.89 (1.66, 2.12) 1.69 (1.56, 1.83) 0.080
Adiponectin μg/ml 17.5 (16.0, 19.1) 16.7 (15.80, 17.6) 0.377
Insulin mIU/L 10.77 (9.43, 12.12) 9.52 (8.74, 10.29) 0.224
Log-Leptin ng/ml 2.95 (2.87, 3.03) 2.62 (2.58, 2.67) 0.013
CRP mg/L 5.07 (4.29, 5.85) 3.69 (3.24, 4.14) 0.041
PGF2 pg/ml 2.58 (2.23, 2.93) 2.72 (2.52, 2.92) 0.408
Fasting glucose mmol/L 5.62 (5.40, 5.84) 5.64 (5.52, 5.77) 0.949
2 hour glucose mmol/L 7.62 (7.05, 8.19) 7.64 (7.31, 7.96) 0.896
HbA1c % 5.88 (5.75, 6.01) 5.93 (5.86, 6.01) 0.384
HOMA IR 2.78 (2.34, 3.22) 2.53 (2.27, 2.78) 0.470
aAdjusted for: age, sex, ethnicity, body mass index, Index of Multiple Deprivation, International Physical Activity Questionnaire score and smoking status.
https://doi.org/10.1371/journal.pone.0187448.t003
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relationship was found in women. Further analysis showed that mean CRP levels were higher
in women compared with men (p0.001).
3.6 The interaction of gender
Interaction analysis revealed that the association each biomarker and depressive symptoms
did not significantly differ with gender within this cohort.
4. Discussion
The aim of the present cross-sectional analysis was to assess whether depressive symptoms were
associated with an increase in markers for T2DM, CVD and inflammation within a healthy
population. Additionally we hypothesized that any metabolic disturbances would differ with
gender. Analysis of the mixed gender cohort showed that depressive symptoms were positively
associated higher leptin and CRP levels (plus a higher likelihood of smoking and lower physical
activity levels) and these findings agree with previous studies [8, 10, 13]. Stratification of the
data for gender appeared to demonstrate that men and women show a different metabolic pro-
file with depression. Depression in women was associated with a larger waist circumference and
higher levels of adiposity/T2DM related markers specifically HOMA IR, leptin and TNF-α com-
pared with women without depression. Conversely, depression in men was associated with
lower body fat and 49% higher CRP levels compared to men without depression. However,
interaction analysis revealed that the metabolic disturbances associated with depressive symp-
toms did not significantly differ with gender. This may reflect the relatively low number of par-
ticipants included in the current analysis and we feel that further work including a larger cohort
may successfully highlight gender-differences associated with depressive symptoms.
Table 4. A comparison of participants with and without depressive symptoms stratified by sex, adjusted data.
Adjusted Mean (95% CI)a
Men Women
Variable Depressive symptoms
(n = 67)
No depressive symptoms
(n = 279)
P-value Depressive symptoms
(n = 92)
No depressive symptoms
(n = 201)
P-value
Resistin ng/ml 5.50 (4.63, 6.38) 5.34 (4.91, 5.76) 0.687 6.06 (4.63, 7.49) 6.10 (5.04, 7.15) 0.879
Apo B ng/ml 1.11 (1.03, 1.19) 1.16 (1.12, 1.20) 0.421 1.08 (1.01, 1.14) 1.10 (1.05, 1.15) 0.454
Apo A ng/ml 1.47 (1.39, 1.55) 1.48 (1.44, 1.52) 0.845 1.64 (1.57, 1.71) 1.61 (1.55, 1.66) 0.240
HDL cholesterol mmol/
L
1.20 (1.13, 1.28) 1.20 (1.16, 1.24) 0.418 1.46 (1.39, 1.54) 1.51 (1.45, 1.56) 0.984
LDL cholesterol mmol/L 3.38 (3.13, 3.62) 3.57 (3.45, 3.70) 0.138 3.47 (3.26, 3.67) 3.62 (3.48, 3.77) 0.345
IL-6 pg/ml 2.85 (2.34, 3.36) 2.57 (2.31, 2.82) 0.323 2.60 (2.17, 3.03) 2.42 (2.12, 2.72) 0.672
TNF-alpha ng/ml 1.93 (1.50, 2.37) 1.83 (1.61, 2.04) 0.679 1.86 (1.62, 2.09) 1.52 (1.36, 1.69) 0.015
Adiponectin μg/ml 13.0 (11.1, 14.9) 13.1 (12.2, 14.1) 0.401 20.8 (18.3, 23.3) 21.3 (19.5, 23.0) 0.499
Insulin mIU/L 12.13 (9.49, 14.76) 10.70 (9.40, 12.00) 0.714 10.13 (9.04, 11.23) 7.87 (7.09, 8.64) 0.011
Log-Leptin ng/ml 2.37 (2.24, 2.50) 2.21 (2.15, 2.28) 0.189 3.40 (3.29, 3.51) 3.19 (3.11, 3.26) 0.010
CRP mg/L 4.53 (3.47, 5.60) 3.07 (2.55, 3.59) 0.031 5.39 (4.18, 6.60) 4.50 (3.64, 5.34) 0.427
PGF2 pg/ml 2.44 (1.90, 2.97) 2.64 (2.37, 2.90) 0.447 2.62 (2.13, 3.11) 2.79 (2.44, 3.14) 0.647
Fasting glucose mmol/L 5.92 (5.51, 6.33) 5.83 (5.63, 6.03) 0.954 5.39 (5.19, 5.60) 5.38 (5.24, 5.53) 0.871
2 hour glucose mmol/L 8.33 (7.32, 9.33) 7.84 (7.34, 8.33) 0.493 7.19 (6.54, 7.83) 7.41 (6.95, 7.86) 0.619
HbA1c % 5.98 (5.74, 6.22) 5.96 (5.84, 6.08) 0.792 5.81 (5.67, 5.94) 5.89 (5.79, 5.98) 0.331
HOMA IR 3.30 (2.42, 4.19) 2.95 (2.51, 3.38) 0.902 2.51 (2.19, 2.83) 1.95 (1.72, 2.17) 0.026
aAdjusted for: age, ethnicity, body mass index, Index of Multiple Deprivation,International Physical Activity Questionnaire score and smoking status.
https://doi.org/10.1371/journal.pone.0187448.t004
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4.1 Elevated adiposity, IR, leptin and tnf-α in women
Systematic reviews have found a significant relationship between adiposity and depression [41,
42]; with more in depth studies revealing that the strongest association is found between
depression and central obesity levels and our data agrees with these findings [43, 44]. One pro-
posed mechanism for the higher central obesity with depression is thought to be an increased
intake of calorie dense foods which preferentially cause increases in omental fat [45, 46].
Within the present study, HOMA IR and leptin were significantly higher in women with
depressive symptoms, however this association was attenuated by accounting for waist circum-
ference and this is in line with previous studies [13, 28, 47, 48, 49]. However, whilst omental
fat clearly has a role in mediating the link between depression and IR and leptin levels, within
the present study regression analysis of waist circumference vs. HOMA IR and leptin showed
that the associations were relatively modest (R2 = 0.188 and 0.368), suggesting that other path-
ways, such as depression-linked excitation of the HPA axis, may also play a significant role in
inducing metabolic derangement.
The above discussion suggests that depression leads to increases IR and leptin, however,
due the cross-sectional design of this study the directionality of the association can not be
proven. Some studies have shown that high baseline levels (or administration) of leptin and
TNF-α lead to increased rates of de novo depression/onset depression-like symptoms [28, 50].
Therefore, it may be the case that an increase in central obesity contributes to an up-regulation
of leptin and inflammatory factors which in turn leads to the onset depressive symptoms,
whilst elevated IR seen with depression is purely a reflection of higher central adiposity.
4.2 Clinical relevance of elevated IR, leptin and TNF-α
The finding that HOMA IR was 28.7% higher with depressive symptoms suggests an increased
risk of developing T2DM. Additionally, a prospective study by Facchini et al (2001) reported
that IR was an independent predictor of cardiovascular disease, stroke, hypertension and can-
cer [51]. The elevated levels of TNF-α seen within the female cohort with depressive symptoms
also represents an adverse metabolic profile as it is well recognised that elevations in TNF-α
are associated with impaired glucose tolerance and IR, indeed, short-term TNF-α infusions
have been shown to induce insulin resistance in healthy lean subjects [52]. Additionally, eleva-
tions in proinflammatory cytokines have been shown to lead to a decrease in serotonin pro-
duction (reviewed by [53]) and therefore may perpetuate depression. Elevated leptin levels
have been implicated in the development of hypertension in human and animal models [54,
55]. Moreover, hyperleptinemia has been associated with subclinical markers of atherosclerosis
such as coronary calcifications and carotid artery intima-media thickness, indeed leptin inhibi-
tion has been postulated to be a promising strategy to slow atherogenesis in hyperleptinemic
individuals [24].
4.3 Elevated CRP in men
Previous reports have shown that CRP is significantly elevated with depression, particularly in
men and the results of this study agree with these findings [56, 57]. Again the directionality
between high CRP and depressive symptoms cannot be inferred from these results. A longitu-
dinal study (in women) carried out by Pasco and colleagues reported a positive association
between high baseline CRP levels and increased risk of de novo major depression, in those
with no previous history of depression [22]. The findings of Pasco et al are supported by the
finding that proinflammatory cytokines activate the enzyme indoleamine-2,3-dioxygenase, an
activation which leads to decreased production of serotonin (reviewed by [53]).
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In line with women, men also showed a trend towards higher IR, leptin and TNF-α with
depressive symptoms but within this cohort this did not reach significance (Table 4). This fact
is interesting in light of the lower body fat % (and marginally lower BMI and waist circumfer-
ence) shown in men with depressive symptoms. This finding suggests adiposity independent
pathways may be driving metabolic derangement in men.
4.4 Clinical relevance of elevated CRP
CRP is recognised as an accurate predictor of future cardiovascular events with, 0-1mg/L pre-
dicting<6% risk of a cardiovascular event in the next 10 years (low risk), 1-3mg/L predicting a
6–20% risk (average risk) and >3-10mg predicting >20% risk (high risk) [58]. The male
cohort without depression showed a mean CRP value of 3.07mg/L (95% CI 2.55,3.59) whilst
the depressed cohort showed a mean value of 4.53mg/L (95% CI 3.47,5.60) and although both
cohorts largely fall within the high risk category, the cohort with depressive symptoms are
clearly at higher risk. Interestingly, there is evidence that systemic inflammation falls following
remission of depression [59], additionally Elovainio and colleagues (2009) found that the more
recent the diagnosed depression or depressive episode was, the stronger the relationship
between depression and high CRP [57]. Therefore, amelioration of depressive episodes
through psychotherapy/medication should have a significant impact on future metabolic
morbidity.
4.5 Potential treatment of depression
As already outlined, due to the cross-sectional design of the present study it is possible that
increases in inflammation and markers of T2DM and CVD precede the onset of symptoms of
depression. This data potentially suggest that, for example, depression in women may respond
to therapies aimed to reduce omental fat (diet and exercise) and TNF blockade medications
[60]. Conversely depression in men is perhaps less likely to respond to weight-reducing thera-
pies but may respond well to anti-depressant treatments that have been shown to be efficacious
in individuals with high baseline CRP levels [60,61]. Having the ability match patients with
treatment based on a variety of variables, including gender, and should help achieve the goal of
highly personalised treatment, however further work on larger cohorts is required to ascertain
whether true gender differences exist.
4.6 Strengths and limitations of the study
The main strengths of this study were that the data was adjusted for a wide range of potential
confounders. Additionally, this study assessed a broad range of clinical and research biomark-
ers associated with T2DM, CVD and inflammation. However, we feel that the due to the rela-
tively low number of participants included in this study (n = 639) we were unable to prove a
significant difference between depressive symptoms and metabolic status in men and women.
Additionally, this is a secondary analysis of a study designed to test a different primary hypoth-
esis and therefore some measurement bias and residual confounding is likely. The temporal
relationship between depressive symptoms and metabolic disturbances could not be estab-
lished due to the cross-sectional design of the study. History of depression (depression dura-
tion and severity) and antidepressant/psychiatric medications were not taken into account,
additionally, clinical diagnosis of depression was not confirmed in accordance with the Diag-
nostic and Statistical Manual of Mental Disorders (DSM-5)[62]. One further point to discuss
is that Awata and colleagues have shown that the WHO (5) with a cut off of13 has 100%
sensitivity (i.e. 100% of depressed people were captured using this cut off) and 78% specific-
ity compared with the clinical gold standard diagnosis of depression [35]. It could be argued
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that this cut-off categorises some individuals without depressive symptoms within the
depressive symptoms group, therefore ‘diluting the data’. Therefore it is likely that further
studies including a more stringent depression screen could increase the significance of the
present findings.
5. Conclusion
This study supports the theory that symptoms of depression are associated with metabolic
disturbances. Whilst women with depressive symptoms had significantly higher risk factors
associated with diabetes (central obesity levels, IR, leptin and TNF-α), depression in men
was associated with higher levels of CRP which potentially suggests an increased risk of
CVD. However, within the present cohort whilst each gender showed distinct trends, no sig-
nificant gender difference was found. It is possible that further work assessing larger cohorts
may reveal a significant gender difference between depressive symptoms and metabolic
status.
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